Exact Mass: 273.0728
Exact Mass Matches: 273.0728
Found 114 metabolites which its exact mass value is equals to given mass value 273.0728
,
within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error
0.001 dalton.
Tolcapone
Tolcapone is a drug that inhibits the enzyme catechol-O-methyl transferase (COMT). It is used in the treatment of Parkinsons disease as an adjunct to levodopa/carbidopa medication. It is a yellow, odorless, non-hygroscopic, crystalline compound. Tolcapone is associated with a risk of hepatotoxicity. [Wikipedia] D002491 - Central Nervous System Agents > D018726 - Anti-Dyskinesia Agents > D000978 - Antiparkinson Agents D004791 - Enzyme Inhibitors > D065098 - Catechol O-Methyltransferase Inhibitors N - Nervous system > N04 - Anti-parkinson drugs > N04B - Dopaminergic agents C78272 - Agent Affecting Nervous System > C38149 - Antiparkinsonian Agent
Ketamine hydrochloride
D018377 - Neurotransmitter Agents > D018683 - Excitatory Amino Acid Agents > D018691 - Excitatory Amino Acid Antagonists D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants > D000777 - Anesthetics D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents C78272 - Agent Affecting Nervous System > C245 - Anesthetic Agent D002491 - Central Nervous System Agents > D000700 - Analgesics
Modafinil
Modafinil is a stimulant drug marketed as a wakefulness promoting agent and is one of the stimulants used in the treatment of narcolepsy. Narcolepsy is caused by dysfunction of a family of wakefulness-promoting and sleep-suppressing peptides, the orexins, whose neurons are activated by modafinil. The prexin neuron activation is associated with psychoactivation and euphoria. The exact mechanism of action is unclear, although in vitro studies have shown it to inhibit the reuptake of dopamine by binding to the dopamine reuptake pump, and lead to an increase in extracellular dopamine. Modafinil activates glutamatergic circuits while inhibiting GABA. N - Nervous system > N06 - Psychoanaleptics > N06B - Psychostimulants, agents used for adhd and nootropics > N06BA - Centrally acting sympathomimetics D002491 - Central Nervous System Agents > D000697 - Central Nervous System Stimulants > D064690 - Wakefulness-Promoting Agents D065693 - Cytochrome P-450 Enzyme Inducers > D065701 - Cytochrome P-450 CYP3A Inducers COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials C78272 - Agent Affecting Nervous System > C47795 - CNS Stimulant Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS
Nebicapone
C78272 - Agent Affecting Nervous System > C38149 - Antiparkinsonian Agent C471 - Enzyme Inhibitor
Pomalidomide
C308 - Immunotherapeutic Agent > C129820 - Antineoplastic Immunomodulating Agent > C157388 - Immunomodulatory Imide Drug L - Antineoplastic and immunomodulating agents > L04 - Immunosuppressants > L04A - Immunosuppressants D006133 - Growth Substances > D043924 - Angiogenesis Modulating Agents D000970 - Antineoplastic Agents > D020533 - Angiogenesis Inhibitors C274 - Antineoplastic Agent > C1742 - Angiogenesis Inhibitor D006133 - Growth Substances > D006131 - Growth Inhibitors D007155 - Immunologic Factors
(3R),5-dihydroxy-(4S)-methyl-3,4-dihydro-2,9,10-(2H)-1-azaanthracenetrione|laoticuzanone A
Pomalidomide
C308 - Immunotherapeutic Agent > C129820 - Antineoplastic Immunomodulating Agent > C157388 - Immunomodulatory Imide Drug L - Antineoplastic and immunomodulating agents > L04 - Immunosuppressants > L04A - Immunosuppressants D006133 - Growth Substances > D043924 - Angiogenesis Modulating Agents D000970 - Antineoplastic Agents > D020533 - Angiogenesis Inhibitors C274 - Antineoplastic Agent > C1742 - Angiogenesis Inhibitor D006133 - Growth Substances > D006131 - Growth Inhibitors D007155 - Immunologic Factors
Tolcapone
D002491 - Central Nervous System Agents > D018726 - Anti-Dyskinesia Agents > D000978 - Antiparkinson Agents D004791 - Enzyme Inhibitors > D065098 - Catechol O-Methyltransferase Inhibitors N - Nervous system > N04 - Anti-parkinson drugs > N04B - Dopaminergic agents C78272 - Agent Affecting Nervous System > C38149 - Antiparkinsonian Agent CONFIDENCE standard compound; INTERNAL_ID 273; DATASET 20200303_ENTACT_RP_MIX505; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 4727; ORIGINAL_PRECURSOR_SCAN_NO 4722 CONFIDENCE standard compound; INTERNAL_ID 273; DATASET 20200303_ENTACT_RP_MIX505; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 4810; ORIGINAL_PRECURSOR_SCAN_NO 4806 CONFIDENCE standard compound; INTERNAL_ID 273; DATASET 20200303_ENTACT_RP_MIX505; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 4841; ORIGINAL_PRECURSOR_SCAN_NO 4839 CONFIDENCE standard compound; INTERNAL_ID 273; DATASET 20200303_ENTACT_RP_MIX505; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 4812; ORIGINAL_PRECURSOR_SCAN_NO 4809 CONFIDENCE standard compound; INTERNAL_ID 273; DATASET 20200303_ENTACT_RP_MIX505; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 4900; ORIGINAL_PRECURSOR_SCAN_NO 4896 CONFIDENCE standard compound; INTERNAL_ID 273; DATASET 20200303_ENTACT_RP_MIX505; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 4752; ORIGINAL_PRECURSOR_SCAN_NO 4748
provigil
N - Nervous system > N06 - Psychoanaleptics > N06B - Psychostimulants, agents used for adhd and nootropics > N06BA - Centrally acting sympathomimetics D002491 - Central Nervous System Agents > D000697 - Central Nervous System Stimulants > D064690 - Wakefulness-Promoting Agents D065693 - Cytochrome P-450 Enzyme Inducers > D065701 - Cytochrome P-450 CYP3A Inducers COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials C78272 - Agent Affecting Nervous System > C47795 - CNS Stimulant Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS
2-Methoxy-3-nitro-[1,1-biphenyl]-3-carboxylic acid
Ethanone,1-(2,4-dihydroxyphenyl)-2-(4-nitrophenyl)-
3-amino-3-(1,3-benzodioxol-5-yl)-2,2-dimethylpropanoic acid,hydrochloride
3-[5-(2-METHYL-4-NITRO-PHENYL)-FURAN-2-YL]-ACRYLIC ACID
5-amino-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione
4-(Aminomethyl)-4-(3,4-dichlorophenyl)cyclohexanol
esketamine hydrochloride
C78272 - Agent Affecting Nervous System > C265 - Antidepressant Agent
METHYL3-{[2-(DIAMINOMETHYLENEAMINO)THIAZOL-4-YL]METHYLTHIO}PROPANIMIDATE
4-(aminomethyl)-4-(3,4-dichlorophenyl)cyclohexan-1-ol
2-(4-methoxy-N-methylsulfonylanilino)propanoic acid
3-(2-PHENYL-IMIDAZOL-1-YL)-PROPYLAMINE DIHYDROCHLORIDE
5,6-dimethoxy-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid,hydrochloride
(S)-(-)- 6,7-DIMETHOXY-1,2,3,4-TETRAHYDROISOQUINOLINE-3- CARBOXYLIC ACID HYDROCHLORIDE
6-nitro-4-oxo-7-propan-2-yloxy-1H-quinoline-3-carbonitrile
2-Pyridin-4-yl-benzo[h]chromen-4-one
D004791 - Enzyme Inhibitors > D001571 - Benzoflavones
Ethyl morpholine-2-carboxylate 2,2,2-trifluoroacetate
5-propan-2-yl-7-(trifluoromethyl)pyrazolo[1,5-a]pyrimidine-2-carboxylic acid
Methyl 2-amino-5-(3-chloropropoxy)-4-methoxybenzoate
2-(Benzofuran-2-yl)-6-methyl-1,3,6,2-dioxazaborocane-4,8-dione,2-Benzofuranboronic acid MIDA ester
armodafinil
N - Nervous system > N06 - Psychoanaleptics > N06B - Psychostimulants, agents used for adhd and nootropics > N06BA - Centrally acting sympathomimetics D002491 - Central Nervous System Agents > D000697 - Central Nervous System Stimulants > D064690 - Wakefulness-Promoting Agents D065693 - Cytochrome P-450 Enzyme Inducers > D065701 - Cytochrome P-450 CYP3A Inducers C78272 - Agent Affecting Nervous System > C47795 - CNS Stimulant
6-[N-(2-chloropyrimidin-4-yl)amino]-2,3-dimethyl-2H-indazole
4-METHYL-N-(4-METHYL-BENZYLIDENE)BENZENESULFONAMIDE
2-(tert-Butylamino)-3,4-chloropropiophenone hydrochloride
(S)-6,7 DIMETHOXY 1,2,3,4 TETRAHYDRO-ISOQUINOLINE-3-CARBOXYLOIC ACID HYDROCHLORIDE
4-(6-Chloro-2-Methylsulfanyl-pyriMidin-4-ylaMino)-cyclohexanol
1-(1-methylpyrazol-4-yl)sulfonylpiperidine-4-carboxylic acid
4,7-Methano-1H-(1,2)diazeto(3,4-f)benzotriazole, 1-(4-chlorophenyl)-3a,4,4a,6a,7,7a-hexahydro-
2-methyl-N-[(E)-(2-nitrophenyl)methylideneamino]furan-3-carboxamide
2-[(4-Chloro-2-methylphenoxy)methyl]imidazo[1,2-a]pyrimidine
3-(4-chlorophenyl)-2,5-dimethyl-1H-pyrazolo[1,5-a]pyrimidin-7-one
2-(4-Chlorophenoxy)-4-(dimethylamino)-3-pyridinecarbonitrile
Ketalar
D018377 - Neurotransmitter Agents > D018683 - Excitatory Amino Acid Agents > D018691 - Excitatory Amino Acid Antagonists D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants > D000777 - Anesthetics D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents D002491 - Central Nervous System Agents > D000700 - Analgesics
N-(5-fluoro-2-methylphenyl)-1,3-benzodioxole-5-carboxamide
N-[4-cyano-5-methyl-2-oxo-3-(trifluoromethyl)-1H-pyrrol-3-yl]cyclopropanecarboxamide
3-(1,3-Benzoxazol-2-ylsulanyl)-5,5-dimethylcyclohex-2-en-1-one
2-(4-chlorophenyl)-N-[(E)-pyridin-4-ylmethylideneamino]acetamide
2-(N-Benzyloxycarbonyl-N-methylamino)ethylphosphonic acid
8,10-dimethoxy-4,12,14-trioxa-2-azatetracyclo[7.7.0.0³,⁷.0¹¹,¹⁵]hexadeca-1(16),2,5,7,9,11(15)-hexaene
4-hydroxy-2-{[hydroxy(2-hydroxyphenyl)methylidene]amino}benzoic acid
16-methoxy-2-methyl-4,12,14-trioxa-2-azatetracyclo[7.7.0.0³,⁷.0¹¹,¹⁵]hexadeca-1(16),3(7),5,9,11(15)-pentaen-8-one
2-benzamidobenzoic acid; 2',4-dihydroxy
{"Ingredient_id": "HBIN005343","Ingredient_name": "2-benzamidobenzoic acid; 2',4-dihydroxy","Alias": "NA","Ingredient_formula": "C14H11NO5","Ingredient_Smile": "NA","Ingredient_weight": "273.24","OB_score": "NA","CAS_id": "115610-40-7","SymMap_id": "NA","TCMID_id": "NA","TCMSP_id": "NA","TCM_ID_id": "8694","PubChem_id": "NA","DrugBank_id": "NA"}